Prestige Consumer Healthcare (PBH)
Builds and markets an acquisition-led portfolio of OTC health and personal-care brands.
Something off on this page? Send us feedback.
Develops and markets acquired OTC health and personal-care brands spanning better breathing, women’s health, eye care, digestive care, pain relief, and therapeutic skin care. North America drives most sales, while international exposure is expanding through Breathe Right and Australia-based LaCorium.
Develops, markets, and distributes over-the-counter health and personal-care brands across better breathing, women’s health, eye and ear care, digestive care, pain relief, oral care, dermatology, pediatric care, and sleep. Breathe Right, now its largest brand, joins Monistat, Summer’s Eve, Clear Eyes, TheraTears, Dramamine, Fleet, and DenTek; the LaCorium acquisition adds Dermal Therapy in Australian therapeutic skin care.
Runs an acquisition-led model that pairs established brands with advertising, product extensions, and broad retail distribution. North America supplies most revenue, while Australia, Europe, and other international markets form a smaller but expanded footprint.
Operates through North American OTC Healthcare and International OTC Healthcare. Production is mostly outsourced, sales are concentrated among major retail and e-commerce customers, and products are governed by FDA and foreign regulations.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 14, 2026 | Oppenheimer | Downgrade | ||
| Jan 30, 2026 | Jefferies | Target | Target: $71 | Target: $66 |
| Oct 27, 2025 | Jefferies | Reiterate | Rating: —Target: — | Target: $71 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $89.1M · Total debt $2.06B · Total assets $4.57B · Shareholders' equity $1.92B
- Revenue
- $265.7M
- Operating income
- $52.5M
- Net income
- $29.2M
No dividends on record.
| Institutions | 114.87% | 54.42M shares | |
|---|---|---|---|
| 320 holders · as of Jun 30, 2026 | |||
| Insiders | 1.45% | 685.2K shares | |
| 13 holders · as of Aug 5, 2026 | |||
| Adds to | 116.32% | ||
47.37M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 116.32%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 16.53% | 7.83M | as of Jun 30, 2026 |
Ariel Investments, LLCInstitution | 10.28% | 4.87M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.96% | 2.83M | as of Jun 30, 2026 |
Dimensional Fund Advisors LPInstitution | 5.62% | 2.66M | as of Jun 30, 2026 |
Fuller & Thaler Asset Management, Inc.Institution | 4.92% | 2.33M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 11, 2026 | Jeffrey Zerillo | officer: Senior VP Operations | −351 | $52.28 |
| May 7, 2026 | Jeffrey Zerillo | officer: Senior VP Operations | −305 | $54.36 |
| May 5, 2026 | Jeffrey Zerillo | officer: Senior VP Operations | −1,553 | $55.06 |
| Feb 11, 2026 | Jeffrey Zerillo | officer: Senior VP Operations | −1,000 | $65.93 |
| Dec 1, 2025 | Jeffrey Zerillo | officer: Senior VP Operations | −281 | $60.00 |
- Haleon (ADR)
Broad consumer-health pure play across oral, pain, respiratory, and GI
- Kenvue
Consumer-health pure play spanning OTC self care, eye, oral, and baby care
- Perrigo
Store-brand and self-care OTC rival across retailer shelves
- Church & Dwight
Oral, cold-remedy, women's-health, and personal-care brand overlap
- Procter & Gamble
Scale competitor in personal health, oral care, and feminine care
- Alcon
Focused eye-care competitor against drops and ocular-health brands
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Prestige Consumer Healthcare | $47.44 | +1.37% | $2.22B | 13.1 | 10.1 | 2.0 | +6.5% |
| Haleon (ADR) | $9.28 | −0.91% | $41.22B | 19.5 | — | 2.8 | +3.7% |
| Kenvue | $17.89 | +1.22% | $33.93B | 20.3 | 15.0 | 2.2 | +3.0% |
| Perrigo | $14.35 | +1.56% | $1.96B | — | 6.1 | 0.5 | −3.2% |
| Church & Dwight | $95.97 | +0.51% | $22.62B | 30.8 | 24.6 | 3.6 | +1.6% |
| Procter & Gamble | $147.70 | +1.11% | $347.33B | 22.1 | 21.1 | 4.0 | +1.5% |
| Alcon | $65.55 | +1.04% | $31.64B | 49.9 | 17.3 | 2.9 | +7.5% |
| Median | 22.1 | 17.3 | 2.8 | +2.3% |